Drug intelligence / Profile preview

methimazole + pentoxifylline

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two medications. Methimazole is a thionamide antithyroid agent that inhibits thyroid hormone synthesis by blocking the action of thyroid peroxidase, leading to reduced hyperthyroidism. Pentoxifylline is a methylxanthine derivative that improves blood flow and circulation by making blood thinner and blood vessels wider. While methimazole is primarily used for hyperthyroidism, pentoxifylline has shown beneficial effects in thyroid-associated ophthalmopathy (TAO) by reducing inflammatory symptoms and associated laboratory parameters.

Targets

TPO (Thyroid peroxidase)PDE (Phosphodiesterase family)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on methimazole + pentoxifylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methimazole + pentoxifylline.

Explore the full profile